case_images: PMC4516340_01
case_images: Baseline OCT and contour maps of right (A) and left (B) eyes at 1 week post-PGE1 injection; OCT with difference map of right (C) and left (D) eyes; and posttreatment OCT with difference maps of right (E) and left (F) eyes.. Abbreviations: OCT, optical coherence tomography; OD, right eye; OS, left eye; PGE1, prostaglandin E1; VA, visual acuity.
case_images: imcrj-8-141Fig1.jpg
case_images: PMC4516340_01_imcrj-8-141Fig1.jpg
case_images: f1-imcrj-8-141
case_images: Serendipitously, he had been evaluated 1 week prior for monitoring of his nonexudative macular degeneration (MD) and mild ME associated with epiretinal membrane (ERM) OU (Figure 1A and B). OS > OD and nonexudative MD OU. OCT studies revealed CME with an increase in central macular thickness of 17 microm OD and 94 microm OS (Figure 1C and D).
case_images: Fluorescein angiography 1 week following systemic injection of PGE1 of right (A) and left (B) eyes, and following treatment of right (C) and left (D) eyes.. Note: White arrows and gray arrows define the area of CME before and after treatment, respectively.. Abbreviations: CME, cystoid macular edema; PGE1, prostaglandin E1.
case_images: imcrj-8-141Fig2.jpg
case_images: PMC4516340_01_imcrj-8-141Fig2.jpg
case_images: f2-imcrj-8-141
case_images: FA studies showed no evidence of exudative conversion and revealed CME OU with optic nerve hyperfluorescence, OS > OD (Figure 2A and B). F). FA studies revealed resolution of active macular leakage, with no evidence of exudative MD 7 months following treatment (Figure 2C and D).